1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Extended follow‐up from the phase 2 CheckMate 436 study
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Key genetic and molecular aberrations identified in both adult and EBV‐positive Burkitt lymphoma patients
    Meeting Abstract

    Orem, J.; Martin, M. R.; Mbulaiteye, S. M.; Mullighan, C. G.; Mungall, A. J.; Mungall, K.; Namirembe, C.; Noy, A.; Petrello, H.; Ogwang, M. D.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Predictive value of quantitative (18)F‐FDG‐PET‐CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Moskowitz, A. J.; Kersten, M. J.; Moskowitz, C. H.; Eertink, J. J.; van de Brug, T.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Real‐world treatment patterns and outcomes of 3455 previously untreated mantle cell lymphoma patients in US routine clinical practice
    Meeting Abstract

    Kumar, A.; Martin, P.; Wang, M.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics of patients achieving complete or partial response (CR/PR) with tazemetostat (TAZ) in wild‐type relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Salles, G.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Campbell, P.; Ribrag, V.; Laurent Damaj, G.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Estimation of long‐term survival with tafasitamab + lenalidomide (LEN) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Salles, G.; Goswami, B.; Bagnardi, V.; Dey, D.; Winderlich, M.; Ambarkhane, S.; Huang, D.; Nowakowski, G. S.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
    Meeting Abstract

    Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Time to second line Bruton tyrosine kinase therapy and age at its initiation are strongly associated with subsequent overall survival in patients with first relapse of mantle cell lymphoma
    Meeting Abstract

    Villa, D.; Jiang, A.; Crosbie, N.; Rule, S.; McCulloch, R.; Visco, C.; Buege, M. J.; Kumar, A.; Bond, D.; Paludo, J.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save